This collaboration is based on the complementarity between the two companies. Seqens brings its skills and expertise as a global leader in small molecules Active Pharmaceutical Ingredients (APIs), from the design and development to the manufacturing of APIs. Rondol brings its expertise in the development and continuous improvement of drug dosage extrusion technologies. The common objective is to accelerate the development and commercialization of extruded dosage forms with improved bioavailability, reduced side effects and optimized manufacturing costs.

A beneficial crossover

Many therapeutic areas can benefit from the crossover of the different technologies for example, oncology, infectious diseases, central nervous system. Those technologies will contribute to develop drugs with potential toxicity concerns and for which the required dosage for treatment is estimated to be high.
The two companies are pooling their expertise to launch more rapidly new biotech inventions. They work to redesign, to lower the cost and reduce the potential side effects of some traditional healthcare treatments. This collaboration could also enable a better and faster response to future pandemics.

“Seqens will bring its skills and expertise in developing and manufacturing small molecules. The group will rely on Rondol expertise in drug dosage extrusion technologies. We count on this collaboration to bring value to our customers. We will further increase our portfolio of cutting-edge technologies and services we master in the Seqens’Lab and in our 6 other R&D centers around the world.” Says Pierre Luzeau, CEO – SEQENS

“Rondol was the 1st company to launch horizontal micro extrusion machines for Pharma applications. They were used to develop Kaletra tablets against HIV. In 2019 we have patented the 1st vertical Pharma extruder that makes it possible to lower the cost and improve the quality of extruded formulations. We see our collaboration with Seqens as a major step to offer our common customers a strong platform of technology expertise. We will bring sound and fast to the market new or repurposed drugs at competitive costs”. Explains Victoire De Margerie – CEO Randol


Learn more